OTS Success Story Feature: LensGen
LensGen presented at Octane’s Ophthalmology Technology Summit in 2018 and raised a total of $42M. They presented as the OTS Sucess Story as part of the LaunchPad Presentation Panel in 2019.
Our 2019 LaunchPad Finalists
Cell Care Therapeutics
Cell Care Therapeutics, a preclinical stage biotechnology company, is pioneering the development of a cell-free biologic derived from the secretions of mesenchymal stem cells for the treatment of degenerative retinal diseases that lead to blindness. This novel product is a cell-free alternative to stem cell therapy that can be stored at room temperature and precisely reconstituted, dosed, and injected in ways that stem cells cannot. The company’s next-generation regenerative therapy will broaden the clinical applicability of regenerative medicine and expand patient access to these new treatment approaches.
IACTA Pharmaceuticals was established by former key Allergan executives to develop and commercialize innovative eyecare products. We’re dedicated to treating diseases, advancing technology and improving patient outcomes. IACTA currently has two products in Phase 2 and two pre-clinical programs.
Lentechs, LLC (“Lentechs”) is a privately-held, clinical stage ophthalmic medical device company focused on developing a portfolio of first-in-class suspended soft contact lenses. The Company’s flagship contact lens platform, APIOC®, is designed based on the natural structures of the eye and curvature of the cornea, utilizing proprietary front and back surfaces, and a patented unique ridge for suspension of the lens from the upper lid.
VisgenX, Inc. is developing therapeutics for “dry” Age- Related Macular Degeneration (AMD) a leading cause of blindness with currently no approved treatments. It affects more than 11 million in the US and > 196 million worldwide and represents a market potential of >$20 billion in the United States alone.